Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since May 27 · below the Ichimoku cloud · RSI 32 · MACD below its signal · at its 52-week low
| 20.03 | 52-week high | +69.03% |
| 14.07 | Previous month high | +18.73% |
| 12.69 | Previous week high | +7.09% |
| 12.59 | Previous month low | +6.20% |
| 12.51 | R3 (classic) | +5.60% |
| 12.38 | R2 (classic) | +4.44% |
| 12.24 | Previous day high | +3.29% |
| 12.11 | R1 (classic) | +2.22% |
| 11.98 | Pivot | +1.07% |
| 11.85 | Price now | |
| 11.84 | Previous day low | −0.08% |
| 11.84 | Previous week low | −0.08% |
| 11.84 | 52-week low | −0.08% |
| 11.71 | S1 (classic) | −1.15% |
| 11.58 | S2 (classic) | −2.31% |
| 11.31 | S3 (classic) | −4.53% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| ARK Investment Management · Cathie Wood | $1.9M | 0.01% | 126.58K | −2.6% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MDWD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Rubinstein SamuelDirector | Sale at price 12.72 per share. | 525 | $6.68K |
| Aug 31, 2026 | Rubinstein SamuelDirector | Purchase at price 12.62 per share. | 525 | $6.63K |
| Aug 26, 2026 | Hess ShmuelChief Operating Officer | Sale at price 12.72 - 13.13 per share. | 5.8K | $75.39K |
| Aug 25, 2026 | Hess ShmuelChief Operating Officer | Conversion of Exercise of derivative security at price 12.70 per share. | 5K | $63.50K |
| Jun 2, 2026 | Shamir NachumDirector | Purchase at price 13.98 - 14.00 per share. | 6K | $84.00K |
| May 31, 2026 | Fox David MortonDirector | Purchase at price 14.00 - 14.23 per share. | 3.5K | $49.90K |
| May 28, 2026 | Rubinstein SamuelDirector | Purchase at price 14.33 per share. | 150 | $2.15K |
TimeframesDown on the hourly, daily and weekly, mixed on the monthly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.8 | -4.6 | -6.9 | 2.4 | -13.2 | 2.6 | -3.9 | -10.7 | 9.2 | -13.9 | −35.8% | ||
| 2025 | 10.0 | -15.2 | -6.5 | 14.1 | 24.0 | -11.8 | -3.8 | -10.4 | 7.9 | 1.7 | -2.2 | 3.0 | +3.7% |
| 2024 | 25.6 | 13.2 | -1.5 | 30.6 | -12.4 | -4.8 | 23.9 | -4.4 | -1.8 | 0.2 | -3.5 | 1.9 | +75.0% |
| 2023 | 2.4 | -6.4 | 3.1 | -13.6 | -20.7 | 16.8 | -11.8 | -11.9 | 28.5 | -24.8 | 11.7 | 13.8 | −24.6% |
| 2022 | 5.5 | -4.0 | -16.7 | 6.5 | -16.5 | 4.0 | -9.2 | 16.8 | -28.7 | -4.3 | 20.3 | 20.4 | −18.3% |
| 2021 | 30.5 | 6.0 | 4.9 | -15.6 | -24.9 | 12.6 | -0.8 | -4.2 | -8.2 | 5.4 | -24.1 | -11.6 | −36.2% |
| 2020 | -2.3 | -8.6 | -43.3 | 27.4 | 2.5 | 44.9 | 32.0 | -6.4 | 2.5 | -17.0 | 20.5 | -1.6 | +19.4% |
| 2019 | 19.7 | 0.2 | 2.7 | 6.4 | -17.5 | -23.0 | -16.6 | 11.7 | 1.6 | -8.4 | 2.0 | 3.7 | −23.6% |
| 2018 | 0.0 | -12.4 | 33.3 | 5.8 | 25.5 | 0.0 | -11.6 | 3.3 | -2.4 | -5.7 | -0.5 | -29.6 | −8.8% |
| 2017 | 23.4 | 5.3 | 10.9 | -9.1 | 15.8 | -2.2 | 0.7 | -8.0 | -15.1 | -5.6 | -8.9 | -3.3 | −2.8% |
| 2016 | -20.8 | 19.4 | 0.0 | 2.5 | -6.9 | 2.5 | -6.3 | 0.9 | 3.2 | -16.9 | -16.4 | -14.4 | −46.4% |
| 2015 | 32.0 | -12.3 | -6.1 | -18.5 | -0.7 | 20.6 | -0.8 | 2.3 | 6.4 | 17.7 | 14.7 | -17.1 | +28.2% |
| 2014 | -28.9 | 15.9 | -4.2 | -23.6 | -16.1 | -13.7 | -6.3 | 0.3 | 12.5 | −53.8% |
Buy / hold / sell counts
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.